• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

南非奥密克戎时代SARS-CoV-2迅速变化的免疫格局和严重程度。

Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa.

作者信息

Sun Kaiyuan, Tempia Stefano, Kleynhans Jackie, von Gottberg Anne, McMorrow Meredith L, Wolter Nicole, Bhiman Jinal N, Moyes Jocelyn, Carrim Maimuna, Martinson Neil A, Kahn Kathleen, Lebina Limakatso, du Toit Jacques D, Mkhencele Thulisa, Viboud Cécile, Cohen Cheryl

机构信息

Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States of America.

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.

出版信息

medRxiv. 2022 Aug 22:2022.08.19.22278993. doi: 10.1101/2022.08.19.22278993.

DOI:10.1101/2022.08.19.22278993
PMID:36032973
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9413704/
Abstract

South Africa was among the first countries to detect the SARS-CoV-2 Omicron variant. Propelled by increased transmissibility and immune escape properties, Omicron displaced other globally circulating variants within 3 months of its emergence. Due to limited testing, Omicron's attenuated clinical severity, and an increased risk of reinfection, the size of the Omicron BA.1 and BA.2 subvariants (BA.1/2) wave remains poorly understood in South Africa and in many other countries. Using South African data from urban and rural cohorts closely monitored since the beginning of the pandemic, we analyzed sequential serum samples collected before, during, and after the Omicron BA.1/2 wave to infer infection rates and monitor changes in the immune histories of participants over time. Omicron BA.1/2 infection attack rates reached 65% (95% CI, 60% - 69%) in the rural cohort and 58% (95% CI, 61% - 74%) in the urban cohort, with repeat infections and vaccine breakthroughs accounting for >60% of all infections at both sites. Combined with previously collected data on pre-Omicron variant infections within the same cohorts, we identified 14 distinct categories of SARS-CoV-2 antigen exposure histories in the aftermath of the Omicron BA.1/2 wave, indicating a particularly fragmented immunologic landscape. Few individuals (<6%) remained naïve to SARS-CoV-2 and no exposure history category represented over 25% of the population at either cohort site. Further, cohort participants were more than twice as likely to get infected during the Omicron BA.1/2 wave, compared to the Delta wave. Prior infection with the ancestral strain (with D614G mutation), Beta, and Delta variants provided 13% (95% CI, -21% - 37%), 34% (95% CI, 17% - 48%), and 51% (95% CI, 39% - 60%) protection against Omicron BA.1/2 infection, respectively. Hybrid immunity (prior infection and vaccination) and repeated prior infections (without vaccination) reduced the risks of Omicron BA.1/2 infection by 60% (95% CI, 42% - 72%) and 85% (95% CI, 76% - 92%) respectively. Reinfections and vaccine breakthroughs had 41% (95% CI, 26% - 53%) lower risk of onward transmission than primary infections. Our study sheds light on a rapidly shifting landscape of population immunity, along with the changing characteristics of SARS-CoV-2, and how these factors interact to shape the success of emerging variants. Our findings are especially relevant to populations similar to South Africa with low SARS-CoV-2 vaccine coverage and a dominant contribution of immunity from prior infection. Looking forward, the study provides context for anticipating the long-term circulation of SARS-CoV-2 in populations no longer naïve to the virus.

摘要

南非是最早检测到严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎变异株的国家之一。由于其传播性增强和免疫逃逸特性,奥密克戎在出现后的3个月内就取代了其他全球流行的变异株。由于检测有限、奥密克戎的临床严重程度减弱以及再感染风险增加,奥密克戎BA.1和BA.2亚变体(BA.1/2)浪潮的规模在南非和许多其他国家仍知之甚少。利用自大流行开始以来密切监测的南非城市和农村队列的数据,我们分析了在奥密克戎BA.1/2浪潮之前、期间和之后收集的连续血清样本,以推断感染率并监测参与者免疫史随时间的变化。在农村队列中,奥密克戎BA.1/2感染发病率达到65%(95%置信区间,60% - 69%),在城市队列中达到58%(95%置信区间,61% - 74%),重复感染和疫苗突破感染在两个地点的所有感染中占比均超过60%。结合之前在同一队列中收集的关于奥密克戎变异株出现之前的感染数据,我们在奥密克戎BA.1/2浪潮之后确定了14种不同类别的SARS-CoV-2抗原暴露史,这表明免疫格局特别分散。很少有人(<6%)对SARS-CoV-2仍无感染史,且在两个队列地点,没有任何一种暴露史类别占人口的比例超过25%。此外,与德尔塔浪潮相比,队列参与者在奥密克戎BA.1/2浪潮期间感染的可能性是其两倍多。先前感染原始毒株(带有D614G突变)、贝塔和德尔塔变异株分别对奥密克戎BA.1/2感染提供了13%(95%置信区间,-21% - 37%)、34%(95%置信区间,17% - 48%)和51%(95%置信区间,39% - 60%)的保护作用。混合免疫(先前感染和接种疫苗)以及多次先前感染(未接种疫苗)分别将奥密克戎BA.1/2感染风险降低了60%(95%置信区间,42% - 7)和85%(95%置信区间,76% - 92%)。再感染和疫苗突破感染的传播风险比初次感染低41%(95%置信区间,26% - 53%)。我们的研究揭示了迅速变化的群体免疫格局,以及SARS-CoV-2不断变化的特征,以及这些因素如何相互作用以影响新出现变异株的传播。我们的研究结果对于类似于南非的人群尤其相关,这些人群的SARS-CoV-2疫苗接种率较低,且先前感染产生的免疫力占主导。展望未来,该研究为预测SARS-CoV-2在对该病毒不再易感的人群中的长期传播提供了背景信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb4a/9413704/2ae66b0a4b8b/nihpp-2022.08.19.22278993v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb4a/9413704/ac7878ddd285/nihpp-2022.08.19.22278993v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb4a/9413704/f59b0ee528d2/nihpp-2022.08.19.22278993v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb4a/9413704/271ac02c1a53/nihpp-2022.08.19.22278993v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb4a/9413704/2ae66b0a4b8b/nihpp-2022.08.19.22278993v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb4a/9413704/ac7878ddd285/nihpp-2022.08.19.22278993v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb4a/9413704/f59b0ee528d2/nihpp-2022.08.19.22278993v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb4a/9413704/271ac02c1a53/nihpp-2022.08.19.22278993v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb4a/9413704/2ae66b0a4b8b/nihpp-2022.08.19.22278993v1-f0004.jpg

相似文献

1
Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa.南非奥密克戎时代SARS-CoV-2迅速变化的免疫格局和严重程度。
medRxiv. 2022 Aug 22:2022.08.19.22278993. doi: 10.1101/2022.08.19.22278993.
2
Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa.奥密克戎时代南非迅速变化的 SARS-CoV-2 免疫景观和严重程度。
Nat Commun. 2023 Jan 16;14(1):246. doi: 10.1038/s41467-022-35652-0.
3
Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.新加坡一项全国性队列研究:SARS-CoV-2 感染和疫苗对有医疗记录的奥密克戎 BA.4、BA.5 和 XBB 再感染相关症状的保护免疫作用。
Lancet Infect Dis. 2023 Jul;23(7):799-805. doi: 10.1016/S1473-3099(23)00060-9. Epub 2023 Mar 13.
4
SARS-CoV-2 incidence, transmission and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-2021.2020 - 2021年南非农村和城市地区严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的发病率、传播及再感染情况:PHIRST-C队列研究结果
medRxiv. 2021 Dec 4:2021.07.20.21260855. doi: 10.1101/2021.07.20.21260855.
5
Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022.第三剂 BNT162b2 mRNA 疫苗和既往感染对德尔塔和奥密克戎变异株流行期间预防 SARS-CoV-2 感染的有效性:英国 SIREN 队列研究,2021 年 9 月至 2022 年 2 月。
J Infect. 2024 Jan;88(1):30-40. doi: 10.1016/j.jinf.2023.10.022. Epub 2023 Nov 4.
6
BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.新加坡儿童和青少年中 BNT162b2 疫苗对奥密克戎的保护作用以及既往感染变异株和接种顺序的影响:一项基于人群的队列研究。
Lancet Child Adolesc Health. 2023 Jul;7(7):463-470. doi: 10.1016/S2352-4642(23)00101-3. Epub 2023 May 15.
7
Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.2021 年 8 月至 2022 年 3 月,英国青少年在先前感染和接种疫苗后对 delta(B.1.617.2)和 omicron(B.1.1.529)BA.1 和 BA.2 SARS-CoV-2 变异株的症状性感染的保护作用:一项全国性、观察性、基于检测的病例对照研究。
Lancet Infect Dis. 2023 Apr;23(4):435-444. doi: 10.1016/S1473-3099(22)00729-0. Epub 2022 Nov 24.
8
Risk of SARS-CoV-2 reinfection by vaccination status, predominant variant and time from prior infection: a cohort study, Reggio Emilia province, Italy, February 2020 to February 2022.疫苗接种状态、主要变异株和既往感染后时间对 2020 年 2 月至 2022 年 2 月意大利雷焦艾米利亚省 SARS-CoV-2 再感染风险的影响:一项队列研究。
Euro Surveill. 2023 Mar;28(13). doi: 10.2807/1560-7917.ES.2023.28.13.2200494.
9
Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.医护人员中,mRNA 疫苗接种与未接种者,初次感染奥密克戎(B.1.1.529)BA.1 或 前奥密克戎 SARS-CoV-2 对 BA.2 再感染的保护作用:一项病例对照研究。
Lancet Infect Dis. 2023 Jan;23(1):45-55. doi: 10.1016/S1473-3099(22)00578-3. Epub 2022 Sep 21.
10
Acute and Postacute COVID-19 Outcomes Among Immunologically Naive Adults During Delta vs Omicron Waves.免疫功能正常成年人在德尔塔变异株与奥密克戎变异株流行期间的急性和后期 COVID-19 结局。
JAMA Netw Open. 2023 Feb 1;6(2):e231181. doi: 10.1001/jamanetworkopen.2023.1181.

本文引用的文献

1
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.针对新冠病毒奥密克戎亚谱系的印记抗体反应。
Science. 2022 Nov 11;378(6620):619-627. doi: 10.1126/science.adc9127. Epub 2022 Oct 20.
2
Detecting Waning Serological Response with Commercial Immunoassays: 18-Month Longitudinal Follow-up of Anti-SARS-CoV-2 Nucleocapsid Antibodies.用商业免疫分析法检测 SARS-CoV-2 核衣壳抗体血清学反应衰减:长达 18 个月的纵向随访研究
Microbiol Spectr. 2022 Aug 31;10(4):e0098622. doi: 10.1128/spectrum.00986-22. Epub 2022 Jul 14.
3
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa.
南非出现 SARS-CoV-2 奥密克戎变异株 BA.4 和 BA.5。
Nat Med. 2022 Sep;28(9):1785-1790. doi: 10.1038/s41591-022-01911-2. Epub 2022 Jun 27.
4
Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct.SARS-CoV-2 抗原图谱显示,奥密克戎 BA.1 和 BA.2 具有不同的抗原性。
Sci Immunol. 2022 Sep 23;7(75):eabq4450. doi: 10.1126/sciimmunol.abq4450.
5
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.既往感染和疫苗接种对奥密克戎感染症状的影响。
N Engl J Med. 2022 Jul 7;387(1):21-34. doi: 10.1056/NEJMoa2203965. Epub 2022 Jun 15.
6
Immune boosting by B.1.1.529 Omicron) depends on previous SARS-CoV-2 exposure.免疫增强作用取决于先前的 SARS-CoV-2 暴露情况。
Science. 2022 Jul 15;377(6603):eabq1841. doi: 10.1126/science.abq1841.
7
Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection.有或无前感染史的三剂疫苗接种医护人员感染奥密克戎后的免疫反应
Lancet Infect Dis. 2022 Jul;22(7):943-945. doi: 10.1016/S1473-3099(22)00362-0. Epub 2022 Jun 9.
8
Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California.南加州与 SARS-CoV-2 奥密克戎(B.1.1.529)变异株以及 BA.1/BA.1.1 或 BA.2 亚变异株感染相关的临床结局。
Nat Med. 2022 Sep;28(9):1933-1943. doi: 10.1038/s41591-022-01887-z. Epub 2022 Jun 8.
9
Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes.奥密克戎 BA.1 突破感染促进针对保守表位的跨变体中和及记忆 B 细胞形成。
Sci Immunol. 2022 Sep 16;7(75):eabq2427. doi: 10.1126/sciimmunol.abq2427.
10
SARS-CoV-2 transmission, persistence of immunity, and estimates of Omicron's impact in South African population cohorts.SARS-CoV-2 传播、免疫持久性,以及奥密克戎变异株对南非人群队列影响的评估。
Sci Transl Med. 2022 Aug 24;14(659):eabo7081. doi: 10.1126/scitranslmed.abo7081.